Director, Stem Cell Translation Laboratory
NIH/NCATS, MD, United States
Dr. Ilyas Singeç completed his MD/PhD (summa cum laude) at the Universities of Bonn and Freiburg, Germany. After residency in Clinical Neuropathology (2001-2004), he conducted postdoctoral work at NIH/NINDS and the Sanford Burnham Prebys (SBP) Medical Discovery Institute in La Jolla, CA. He derived the first iPS cell lines at SBP in 2008 and then served as the Director of Cell Reprogramming. Joining Pfizer as a Laboratory Head and Senior Principal Scientist in 2012, he established and directed a new stem cell laboratory and developed human iPS cell-based assays for new target identification and validation for neurological and psychiatric disorders. In 2015, Dr. Singeç joined the NIH National Center for Advancing Translational Sciences (NCATS) as the inaugural Director of the newly established Stem Cell Translation Laboratory (SCTL). The work performed by SCTL centers around the development of clinically relevant quality control standards, improved cell differentiation protocols, and industrial-scale biomanufacturing of human cells for high-throughput drug discovery and regenerative medicine. More recently, SCTL also works on projects related to the opioid crisis (NIH HEAL Initiative). Dr. Singeç has been the recipient of several scientific awards and fellowships from Pfizer, Merck, International Bipolar Foundation, German Research Council (DFG), California Institute for Regenerative Medicine (CIRM), and NIH.
Disclosure information not submitted.
Wednesday, February 9, 2022
12:00 PM – 1:00 PM